← Eichor
Study identifier: NCT06952504 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Condition: Endometrial Cancer  ·  Sponsor: Merck Sharp & Dohme LLC

PhasePhase 3
Planned participants1123
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.

This description comes directly from the study's public registry record.

Talk to the study team

Toll Free Number  ·  1-888-577-8839  ·  Trialsites@msd.com

Always discuss trial participation with your own doctor first.

Locations (261)

University of South Alabama, Mitchell Cancer Institute ( Site 6033)Mobile, Alabama, United StatesRecruiting
Alaska Women's Cancer Care ( Site 6036)Anchorage, Alaska, United StatesRecruiting
CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 5014)Irvine, California, United StatesRecruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 6020)Orange, California, United StatesRecruiting
John Muir Health Cancer Center ( Site 6028)Walnut Creek, California, United StatesRecruiting
Yale University School of Medicine ( Site 6009)New Haven, Connecticut, United StatesRecruiting
MedStar Washington Hospital Center ( Site 5005)Washington D.C., District of Columbia, United StatesRecruiting
Florida Cancer Specialists - South ( Site 7003)Fort Myers, Florida, United StatesRecruiting
UF Health Davis Cancer Pavilion and Shands Med Plaza ( Site 6026)Gainesville, Florida, United StatesRecruiting
Mount Sinai Braman Comprehensive Cancer Center ( Site 6031)Miami Beach, Florida, United StatesRecruiting
AdventHealth Orlando-AdventHealth Medical Group Gynecological Oncology ( Site 6002)Orlando, Florida, United StatesRecruiting
Florida Cancer Specialists ( Site 7002)St. Petersburg, Florida, United StatesRecruiting

+ 249 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06952504